GO:0046122 purine deoxyribonucleoside metabolic process: Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0046122 describes the chemical reactions and pathways involving purine bases covalently bonded to deoxyribose, including deoxyadenosine, deoxyguanosine, and deoxyinosine [1,3].
• These pathways are essential for maintaining balanced deoxynucleotide pools for DNA replication and repair, and their dysregulation leads to genotoxic stress [3,5].
• Key enzymes include adenosine deaminase (ADA), purine nucleoside phosphorylase (PNP), deoxycytidine kinase (DCK), and 5'-nucleotidases (NT5C2), which collectively control deoxyribonucleoside salvage and catabolism [3,4].
• Inherited defects in ADA and PNP cause severe immunodeficiencies due to accumulation of toxic deoxyribonucleosides, particularly in lymphocytes.
• Pharmacological inhibition of purine deoxyribonucleoside metabolism is a cornerstone of leukemia and lymphoma chemotherapy, exemplified by cladribine and fludarabine [4,5].
• CRISPR-based knockout, knock-in, and overexpression models enable precise dissection of these pathways in cancer, immunology, and metabolic research.
Description
Purine deoxyribonucleoside metabolic process (GO:0046122) encompasses the biochemical reactions that synthesize, interconvert, and degrade deoxyribonucleosides containing a purine base (adenine or guanine) linked to deoxyribose [1,3]. These molecules, including deoxyadenosine, deoxyguanosine, and deoxyinosine, serve as precursors for DNA synthesis and as signaling metabolites, and their metabolism is tightly regulated to prevent imbalances that can cause DNA damage or cell death [3,5]. The pathway is particularly important in tissues with high cell turnover, such as the immune system and bone marrow, where deoxyribonucleoside salvage and catabolism are critical for lymphocyte proliferation and survival [3,4]. Research into GO:0046122 has revealed its central role in human disease. Inherited deficiencies in adenosine deaminase (ADA) or purine nucleoside phosphorylase (PNP) lead to the accumulation of toxic deoxyribonucleosides, causing severe combined immunodeficiency (SCID) and related immune disorders. In cancer, altered purine deoxyribonucleoside metabolism supports rapid proliferation and confers resistance to nucleoside analog chemotherapies, making enzymes like deoxycytidine kinase (DCK) and 5'-nucleotidase (NT5C2) attractive therapeutic targets [4,5]. Recent studies also highlight the impact of one-carbon metabolism and folate cycle on deoxyribonucleoside synthesis, linking this pathway to broader metabolic reprogramming in cancer and beyond [1,2,6]. Understanding GO:0046122 is therefore essential for researchers in immunology, oncology, and metabolic biology. This article provides a comprehensive overview of the pathway, its key genes, regulatory mechanisms, disease associations, and the CRISPR-based tools available to study it.
purine deoxyribonucleoside metabolic process At A Glance
| GO ID | GO:0046122 |
|---|---|
| GO term | purine deoxyribonucleoside metabolic process |
| Ontology | biological_process |
| Synonym | purine deoxyribonucleoside metabolism |
| Major function | Maintains balanced pools of purine deoxyribonucleosides for DNA synthesis and repair, and prevents accumulation of toxic intermediates [3,5]. |
| Key enzymes | Adenosine deaminase (ADA), purine nucleoside phosphorylase (PNP), deoxycytidine kinase (DCK), 5'-nucleotidases (NT5C2), and others [3,4]. |
| Associated diseases | Severe combined immunodeficiency (ADA/PNP deficiency), leukemia, lymphoma, and metabolic disorders [3,4,5]. |
| Research methods | CRISPR knockout/knock-in, metabolomics, enzyme assays, and next-generation sequencing [1,8]. |
What Is GO:0046122?
GO:0046122, purine deoxyribonucleoside metabolic process, is defined as the chemical reactions and pathways involving any one of a family of organic molecules consisting of a purine base covalently bonded to a sugar deoxyribose (a deoxyribonucleoside). This includes the biosynthesis, salvage, interconversion, and degradation of deoxyadenosine, deoxyguanosine, deoxyinosine, and their phosphorylated derivatives, as well as the regulation of their intracellular concentrations [1,3].
Why Is purine deoxyribonucleoside metabolic process Important in Cell Biology?
Purine deoxyribonucleoside metabolic process is fundamental to cellular life because it supplies the building blocks for DNA and regulates the balance between proliferation and apoptosis. Disruptions in this pathway are directly linked to immunodeficiency, autoimmunity, and cancer, and the enzymes involved are validated targets for chemotherapy and immunosuppression [3,4,5]. Moreover, recent research has connected this pathway to one-carbon metabolism and serine synthesis, revealing broader metabolic networks that influence cell fate and therapy response [1,2,6]. Thus, studying GO:0046122 offers insights into basic cell biology and translational opportunities for drug development.
• Provides deoxyribonucleotides for DNA replication and repair, essential for cell division and genome stability [3,5].
• Dysregulation causes accumulation of toxic deoxyribonucleosides, leading to lymphocyte death and immunodeficiency.
• Enzymes in this pathway are targets for nucleoside analog drugs used in leukemia, lymphoma, and autoimmune diseases [4,5].
• Links to one-carbon metabolism and folate cycle, influencing methylation reactions and nucleotide synthesis [1,2,6].
• Plays a role in pathogen immune evasion, as bacterial deoxyribonucleosides can neutralize phagocytes.
• Altered in cancer cells, contributing to chemoresistance and metabolic reprogramming [5,8].
• Provides biomarkers for inherited metabolic disorders and treatment monitoring [3,8].
• Enables CRISPR-based functional genomics to identify novel therapeutic targets.
What Happens During purine deoxyribonucleoside metabolic process?
De Novo Synthesis and Salvage of Purine Deoxyribonucleosides
In simple terms: Cells can either build purine deoxyribonucleosides from scratch or recycle them from degraded DNA and RNA.
Purine deoxyribonucleosides are generated through two main routes: de novo synthesis from small molecules like amino acids and one-carbon units, and salvage pathways that recycle free bases and nucleosides [1,3]. The de novo pathway produces inosine monophosphate (IMP), which is subsequently converted to adenosine and guanosine nucleotides. For deoxyribonucleosides, ribonucleotide reductase (RNR) reduces the 2'-OH group of ribonucleotides to produce deoxyribonucleotides, which are then dephosphorylated to deoxyribonucleosides [3,5]. Salvage enzymes such as deoxycytidine kinase (DCK) and purine nucleoside phosphorylase (PNP) interconvert these molecules, ensuring adequate pools for DNA synthesis [3,4].
Interconversion and Catabolism of Deoxyribonucleosides
In simple terms: Once formed, deoxyribonucleosides can be modified or broken down to regulate their levels.
Deoxyadenosine and deoxyguanosine undergo deamination and phosphorolysis. Adenosine deaminase (ADA) converts deoxyadenosine to deoxyinosine, which is further processed by PNP to hypoxanthine and deoxyribose-1-phosphate. Similarly, deoxyguanosine is cleaved by PNP to guanine and deoxyribose-1-phosphate. These reactions are critical for preventing the accumulation of dNTPs, which can inhibit DNA repair and induce apoptosis [3,5]. The balance between salvage and catabolism is tightly controlled by feedback inhibition and enzyme expression levels.
Regulation of Deoxyribonucleoside Pools for DNA Synthesis
In simple terms: Cells adjust the amounts of deoxyribonucleosides to match the needs of DNA replication and repair.
Intracellular deoxyribonucleoside triphosphate (dNTP) pools are regulated by the coordinated action of synthetic and catabolic enzymes. RNR is allosterically controlled by dNTPs, while 5'-nucleotidases (e.g., NT5C2) dephosphorylate nucleoside monophosphates to modulate salvage [4,5]. Disruption of this balance leads to dNTP pool imbalances, which are sensed by DNA damage response pathways and can trigger cell cycle arrest or apoptosis [3,5]. One-carbon metabolism provides methyl groups for de novo purine synthesis, linking this pathway to folate and serine metabolism [1,2,6].
Role in Immune Cell Development and Function
In simple terms: Immune cells are especially sensitive to changes in deoxyribonucleoside levels because they divide rapidly.
Lymphocytes rely heavily on purine salvage and catabolism. In ADA or PNP deficiency, deoxyadenosine and deoxyguanosine accumulate, leading to dATP and dGTP imbalance, inhibition of ribonucleotide reductase, and apoptosis of T and B cells. This mechanism underlies the severe immunodeficiency observed in patients with these inherited defects. Pharmacological inhibition of ADA or PNP with analogs like cladribine exploits this sensitivity to treat lymphoid malignancies [4,5].
Microbial and Host Interactions
In simple terms: Some bacteria produce deoxyribonucleosides that can affect host immune cells.
Staphylococcus aureus secretes death-effector deoxyribonucleosides that neutralize phagocytes, highlighting a role for purine deoxyribonucleoside metabolism in host-pathogen interactions. These bacterial metabolites can interfere with host immune cell function, suggesting that targeting microbial deoxyribonucleoside synthesis could be a therapeutic strategy.
Key Genes Involved in GO:0046122 purine deoxyribonucleoside metabolic process
The following genes encode enzymes and transporters that directly participate in or regulate purine deoxyribonucleoside metabolic process.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ADA | Deaminates adenosine and deoxyadenosine to inosine and deoxyinosine | Deficiency causes SCID; target for immunosuppression |
| PNP | Cleaves deoxyinosine and deoxyguanosine to purine bases and deoxyribose-1-phosphate | Deficiency causes immunodeficiency; target for leukemia therapy [3,5] |
| DCK | Phosphorylates deoxycytidine, deoxyadenosine, and deoxyguanosine to monophosphates | Activates nucleoside analogs; resistance marker in cancer |
| NT5C2 | Dephosphorylates purine and pyrimidine nucleoside monophosphates | Mutations confer resistance to nucleoside analogs in leukemia |
| RRM1 | Ribonucleotide reductase subunit, reduces ribonucleotides to deoxyribonucleotides | Target for cancer therapy; regulates dNTP pools |
| RRM2 | Ribonucleotide reductase subunit, essential for de novo dNTP synthesis | Overexpressed in many cancers; prognostic marker |
| HPRT1 | Salvage enzyme converting hypoxanthine to IMP | Deficiency causes Lesch-Nyhan syndrome; model for purine metabolism |
| APRT | Converts adenine to AMP in salvage pathway | Deficiency causes 2,8-dihydroxyadenine urolithiasis |
| ADSL | Adenylosuccinate lyase in de novo purine synthesis | Deficiency causes neurological disorders |
| ATIC | Bifunctional enzyme in de novo purine synthesis | Target for antifolates; linked to one-carbon metabolism |
| GART | Phosphoribosylglycinamide formyltransferase in purine synthesis | Requires folate cofactors; connects to one-carbon cycle |
| MTHFD2 | Mitochondrial one-carbon enzyme supporting purine synthesis | Overexpressed in cancer; linked to serine metabolism |
| SHMT2 | Serine hydroxymethyltransferase, provides one-carbon units for purine synthesis | Target for cancer metabolism |
| SLC29A1 | Equilibrative nucleoside transporter 1, imports deoxyribonucleosides | Determines drug uptake for nucleoside analogs |
| SLC28A1 | Concentrative nucleoside transporter 1, imports deoxyribonucleosides | Affects bioavailability of nucleoside drugs |
| CMPK1 | Phosphorylates deoxycytidine monophosphate to diphosphate | Supports dNTP synthesis; potential target |
| NME1 | Nucleoside diphosphate kinase, generates dNTPs | Metastasis suppressor; regulates dNTP pools |
| DGUOK | Deoxyguanosine kinase, phosphorylates deoxyguanosine in mitochondria | Deficiency causes mitochondrial DNA depletion syndrome |
How Is purine deoxyribonucleoside metabolic process Regulated?
Purine deoxyribonucleoside metabolic process is regulated at multiple levels. Allosteric regulation of ribonucleotide reductase by dNTPs ensures balanced pools. Enzyme expression is controlled by transcription factors responsive to cell cycle and DNA damage, such as E2F and p53. One-carbon metabolism, through the folate cycle and serine synthesis, supplies methyl groups for de novo purine synthesis and is influenced by nutrients and oncogenic signals [1,2,6]. Additionally, metformin and antifolates impair one-carbon metabolism, indirectly affecting deoxyribonucleoside synthesis. In immune cells, cytokine signaling modulates ADA and PNP expression, linking metabolism to immune activation.
purine deoxyribonucleoside metabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ADA | Severe combined immunodeficiency (SCID) | ADA knockout mice; patient-derived iPSCs |
| PNP | Immunodeficiency, autoimmunity | PNP knockout mice; T-cell lines |
| DCK | Leukemia, drug resistance | DCK knockout leukemia cell lines; xenografts |
| NT5C2 | Relapsed leukemia, chemoresistance | NT5C2 mutant knock-in cell lines |
| HPRT1 | Lesch-Nyhan syndrome | HPRT1 knockout mice; neuronal cell models |
Immunodeficiency and Autoimmunity
Inherited deficiencies in ADA or PNP cause severe combined immunodeficiency (SCID) due to accumulation of toxic deoxyribonucleosides, particularly in lymphocytes. These conditions highlight the critical role of purine deoxyribonucleoside catabolism in immune cell survival. Additionally, altered purine metabolism has been implicated in autoimmune diseases, where nucleoside analogs like cladribine are used to suppress lymphocyte proliferation.
Leukemia and Lymphoma
Purine deoxyribonucleoside metabolism is a validated target in hematological malignancies. Cladribine, fludarabine, and other nucleoside analogs are activated by DCK and incorporated into DNA, causing strand breaks and apoptosis [4,5]. Resistance often arises from DCK deficiency or NT5C2 mutations, underscoring the need for personalized approaches. High expression of RRM1/RRM2 and one-carbon enzymes further supports proliferation and is associated with poor prognosis [1,5].
Metabolic and Neurological Disorders
Defects in purine salvage enzymes such as HPRT1 cause Lesch-Nyhan syndrome, characterized by neurological dysfunction and hyperuricemia. DGUOK mutations lead to mitochondrial DNA depletion syndromes with liver and neurological involvement. These disorders illustrate the tissue-specific consequences of impaired deoxyribonucleoside metabolism.
Host-Pathogen Interactions
Staphylococcus aureus produces deoxyribonucleosides that neutralize phagocytes, suggesting that bacterial purine metabolism can modulate host immunity. Targeting these pathways may offer new strategies against resistant infections.
From purine deoxyribonucleoside metabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ADA affect lymphocyte survival? | ADA knockout cell line (e.g., Jurkat) or primary T cells |
| How do NT5C2 mutations confer drug resistance? | NT5C2 point-mutation knock-in in leukemia cells |
| Can overexpression of DCK sensitize cancer cells to nucleoside analogs? | DCK overexpression in resistant cell lines |
| What is the role of PNP in immune development? | PNP knockout mice or human iPSC-derived lymphocytes |
| How does one-carbon metabolism regulate deoxyribonucleoside synthesis? | SHMT2 or MTHFD2 knockout cancer cells |
| Can CRISPR screening identify new targets in purine metabolism? | Genome-wide CRISPR knockout library in cancer cell lines |
How to Study the purine deoxyribonucleoside metabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS metabolomics | Levels of deoxyribonucleosides and nucleotides | Profiling patient samples or cell models [1,6] |
| Stable isotope tracing | Flux through de novo and salvage pathways | Cancer metabolism studies |
| Enzyme activity assay | Catalytic activity of ADA, PNP, DCK | Diagnosis of immunodeficiency; drug screening [3,4] |
| CRISPR knockout screen | Gene essentiality under purine stress | Target discovery |
| RNA-seq | Transcriptional changes in metabolic genes | Biomarker identification |
| Proteomics | Protein expression and modifications | Pathway analysis |
| Flow cytometry | Apoptosis and cell cycle in lymphocytes | Evaluating nucleoside analog toxicity |
| Xenograft models | In vivo tumor response to drugs | Preclinical testing |
Metabolomics and Flux Analysis
Liquid chromatography-mass spectrometry (LC-MS) can quantify deoxyribonucleosides and their phosphorylated derivatives in cells and tissues [1,6]. Stable isotope tracing with 13C-labeled serine or glucose reveals flux through de novo synthesis and salvage pathways, linking to one-carbon metabolism [1,2].
Enzyme Activity Assays
Enzymatic assays for ADA, PNP, DCK, and 5'-nucleotidases measure catalytic activity in cell lysates or recombinant proteins [3,4]. These assays are used to diagnose inherited deficiencies and to evaluate drug effects.
CRISPR-Based Functional Genomics
Genome-wide CRISPR knockout screens can identify genes essential for proliferation under conditions of purine stress or drug treatment. Knock-in of point mutations (e.g., NT5C2) allows study of drug resistance mechanisms.
Transcriptomics and Proteomics
RNA-seq and quantitative proteomics reveal expression changes in purine metabolic enzymes across disease states or treatments [5,8]. These approaches help identify biomarkers and therapeutic targets.
How CRISPR Can Be Used to Study GO:0046122 purine deoxyribonucleoside metabolic process
Knockout
CRISPR knockout of ADA, PNP, or DCK in cell lines can model inherited deficiencies and reveal metabolic vulnerabilities [3,8]. For example, ADA knockout in Jurkat cells leads to deoxyadenosine accumulation and apoptosis, mimicking SCID phenotypes. Genome-wide knockout screens can identify synthetic lethal interactions with nucleoside analogs.
Point Mutation
Knock-in of specific mutations, such as NT5C2 R367Q or DCK mutations, allows precise study of drug resistance and enzyme function. These models are valuable for testing targeted therapies and understanding structure-function relationships.
Knock-in
Tagged knock-in of metabolic enzymes (e.g., GFP-ADA) enables live-cell imaging and protein interaction studies. Knock-in of reporter genes under endogenous promoters can monitor pathway activity in real time.
Overexpression
Overexpression of DCK or RRM2 sensitizes cancer cells to nucleoside analogs or increases proliferation, respectively [4,5]. Conversely, overexpression of NT5C2 confers resistance. These models help validate targets and predict drug responses.
How EDITGENE Supports purine deoxyribonucleoside metabolic process Research
Researchers studying purine deoxyribonucleoside metabolic process-related genes often need to determine whether a candidate gene is causally involved in disease or drug response. EDITGENE provides a comprehensive suite of CRISPR services to generate precisely engineered cell models, enabling functional validation and therapeutic target discovery.
Contact EDITGENE today to design your custom CRISPR model for purine deoxyribonucleoside metabolic process research.
Frequently Asked Questions About purine deoxyribonucleoside metabolic process
What is GO:0046122?
GO:0046122 is the Gene Ontology term for purine deoxyribonucleoside metabolic process, which includes the chemical reactions and pathways involving purine bases covalently bonded to deoxyribose [1,3].
What genes are involved in purine deoxyribonucleoside metabolic process?
Key genes include ADA, PNP, DCK, NT5C2, RRM1, RRM2, HPRT1, and SLC29A1, among others [3,4,5].
What diseases are associated with purine deoxyribonucleoside metabolic process?
Defects in this pathway cause severe combined immunodeficiency (ADA/PNP deficiency), leukemia, lymphoma, and neurological disorders like Lesch-Nyhan syndrome [3,4,5,8].
How is purine deoxyribonucleoside metabolism regulated?
It is regulated by allosteric feedback on ribonucleotide reductase, enzyme expression, and one-carbon metabolism [1,5].
What drugs target purine deoxyribonucleoside metabolism?
Cladribine, fludarabine, and other nucleoside analogs are used in leukemia and autoimmune diseases [4,5].
What is the role of adenosine deaminase (ADA) in this pathway?
ADA deaminates deoxyadenosine to deoxyinosine, preventing toxic accumulation; its deficiency causes SCID.
How can CRISPR be used to study purine deoxyribonucleoside metabolism?
CRISPR knockout, knock-in, and overexpression models allow functional studies of pathway genes and drug responses.
What methods are used to measure purine deoxyribonucleosides?
LC-MS metabolomics, enzyme activity assays, and stable isotope tracing are commonly used [1,6].
Why is purine deoxyribonucleoside metabolism important in cancer?
Cancer cells rely on it for proliferation and drug resistance; targeting it is a therapeutic strategy [4,5].
What is the connection between one-carbon metabolism and purine deoxyribonucleoside synthesis?
One-carbon metabolism provides methyl groups for de novo purine synthesis, linking serine and folate cycles to deoxyribonucleoside production [1,2,6].
Conclusion
Purine deoxyribonucleoside metabolic process (GO:0046122) is a fundamental pathway that maintains DNA precursor pools and regulates cell survival, with profound implications for immunology, oncology, and metabolic diseases. Its enzymes are validated drug targets, and CRISPR-based models are indispensable for dissecting mechanisms and identifying new therapies. EDITGENE offers comprehensive services to support research in this field, from knockout and knock-in models to library screening and bioinformatics.
References
- 1. Pacold ME et al.. 2016. A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate.. Nat Chem Biol 12(6):452-8 PMID: 27110680
- 2. Chanarin I et al.. 1985. Cobalamin-folate interrelations: a critical review.. Blood 66(3):479-89 PMID: 2862932
- 3. Carson DA et al.. 1978. Deoxyribonucleoside toxicity in adenosine deaminase and purine nucleoside phosphorylase deficiency: implications for the development of new immunosuppressive agents.. Ciba Found Symp PMID: 115660
- 4. Spurgeon S et al.. 2009. Cladribine: not just another purine analogue?. Expert Opin Investig Drugs 18(8):1169-81 PMID: 19604118
- 5. Riscoe MK et al.. 1989. Purine metabolism as a target for leukemia chemotherapy.. Blood Rev 3(3):162-73 PMID: 2676034
- 6. Corominas-Faja B et al.. 2012. Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs.. Aging (Albany NY) 4(7):480-98 PMID: 22837425
- 7. Tantawy E et al.. 2022. Staphylococcus aureus Multiplexes Death-Effector Deoxyribonucleosides to Neutralize Phagocytes.. Front Immunol 13:847171 PMID: 35355997
- 8. Kaneko K. 2025. [Basic Research on Purine Metabolism and Its Clinical Application].. Yakugaku Zasshi 145(6):539-551 PMID: 40451877
